Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Cordis' ExoSeal

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson subsidiary Cordis will enter the vascular closure device market in June with the European debut of its ExoSeal system. The bioabsorbable polyglycolic acid plug system, which is designed to close femoral artery puncture sites, received CE-mark approval in May. "An advantage compared to other devices is the procedural sheath does not need to be changed, which helps promote patient comfort," Cordis claims. Competing systems include Abbott's StarClose and St. Jude Medical's AngioSeal
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT028943

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel